Ovid Therapeutics Inc (OVID) Quote

OVID under $2

OVID................................https://stockcharts.com/h-sc/ui?s=OVID&p=W&b=5&g=0&id=p86431144783

OVID under $2

OVID 3.48 - setup for a freeroll???

$3 netcash-per-share?

Takeda, going forward, to incur all research expenses?

Two Phase-3-commencement announcement catalysts upcoming in 2021?

Two, pivotal Phase 3 clinical studies of soticlestat for Dravet syndrome and Lennox-Gastaut syndrome, operated and funded by Takeda, are expected to commence in 2021. If successful, Takeda estimates that soticlestat could receive approval in its fiscal year 2023.

https://docoh.com/filing/1636651/0001564590-21-044455/OVID-8K/file/2

Oh, the boredom that 6 buy ratings gets you. Poor OVID board.

Slow climb to earnings in a couple weeks.

Held up well during a blood couple of days. Earnings coming up in two weeks.

Up a bit PM... not bad at all after the jump.

Someone just bought 200k share block not long ago we know it’s worth more way more

Holding very well on an ugly day- love it!

15 in 3 months I’ll wait with 300m plus cash and milestones kicking in

Should be a good month for OVID. ;)

* * $OVID Video Chart 03-03-2021 * *

Link to Video - click here to watch the technical chart video

Curling back up..let’s best that intraday high of 4.75 going into power hour!

Looks like a 20 dollar stock soon manipulation at its finest shakeout on bs trades for the big dogs lol this stock worth 8 minimum with that news today now I’m holding for a month to 20 obvious big boys want in cheap

$OVID is screaming for the top after the company announced that Takeda has purchased the rights to a key candidate. https://cnafinance.com/ovid-stock-ovid-therapeutics-climbs-on-takeda-agreement/

$OVID

Nice, $3s very possible today .

BCLI, I made out so far on selling $5 puts for the 18th, have had those awhile and will probably buy them back this week if the stock drops a little. OVID on the other hand my 12/11 $5 puts were already assigned. Not looking good for those, I need a $4 share price by next Friday to break even. BCLI has been a much better play.

The company still at strong buy, by 7 analysts .

I’ve seen some play like this and they had good news after the bad news and it went back up right away, I’m not saying it will happen here, but I think people over react to the news today, should bounce some tomorrow imo, market cap over $420M !!

That’s good enough for me .

Just like BCLI. you will get a 20% jump between now and friday. This always happens, the selling is always overdone on these biotechs

way oversold. They are not a one trick pony

$OVID I’m in should have a nice bounce of this level .

big dip in ah's

3.28 in ah's

This could turn out to be
the best buying day we've
seen a quite a while.

I managed to get 500 shares
at $6.50. Just missed getting
500 at $6.40. Oh well.

I'll try to buy
before 2PM today.

What can we expect from the
presentation tomorrow?

new article out today at PSN:

https://pennystocks.news/why-ovid-therapeutics-is-on-the-radar-of-many-farmaceutical-investors-ovid/

I’m here as well.. wondering when we’ll get that stage 3 news.. also, I see a 100k share wall at 8.40?

* * $OVID Video Chart 06-18-2020 * *

Link to Video - click here to watch the technical chart video

Am I the only one making
big money on this stock?

* * $OVID Video Chart 12-17-2019 * *

Link to Video - click here to watch the technical chart video

* * $OVID Video Chart 11-29-2019 * *

Link to Video - click here to watch the technical chart video

* * $OVID Video Chart 11-27-2019 * *

Link to Video - click here to watch the technical chart video

OVID THERAPEUTICS (NASDAQ:OVID) PRICE TARGET AND CONSENSUS RATING
7 Wall Street analysts have issued ratings and price targets for Ovid Therapeutics in the last 12 months. Their average twelve-month price target is $14.00, suggesting that the stock has a possible upside of 460.00%. The high price target for OVID is $27.00 and the low price target for OVID is $10.00. There are currently 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
https://www.marketbeat.com/stocks/NASDAQ/OVID/price-target/

Ovid Therapeutics Announces Senior Management Promotions in Preparation for Multiple Data Readouts Expected in 2020

https://seekingalpha.com/pr/17683312-ovid-therapeutics-announces-senior-management-promotions-preparation-multiple-data-readouts

1- Price action relative to the biotech sector and signs of accumulation. The stock made a nearly 5% move yesterday on good volume, despite the XBI closing negative.

2. I reviewed the company's updated presentation. The last time I'd looked, they'd been guiding for Fragile X readout in Q4 or close to year end (perhaps the riskiest but least impactful of the 4 expected readouts over the next year). However, now they are guiding for it in early 2020 and I remind members that the ARCADE readout for soticlestat in CDKL5 Deficiency Disorder / Dup15q Syndrome is expected in Q1. I have higher conviction for this second readout, considering promising results we reviewed previously for the ENDYMION open label extension trial.

Given this change, to my eyes it makes it less feasible to wait for the Fragile X readout to get in prior to ARCADE. As preclinical rationale for OV101 appears intriguing and data in FXS mice has shown normalization of certain aspects of Fragile X (anxiety, irritability, repetitive behaviors, hyperactivity), I don't mind being exposed to both readouts (with Angelman to follow midyear).

Market capitalization of around $125 million seems quite reasonable relative to substantial market opportunities being targeted and multi-faceted neurology pipeline (cash position boosted by secondary as well). This is primarily a catalyst idea, as several data events loom in the near to medium term (OV101 in Fragile X and Angelman, soticlestat in phase 2 ARCADE study and phase 2 ELEKTRA trial). OV101 is the only drug in development for Angelman Syndrome, and management appears to have much confidence in achieving the same CGI-I endpoint as the prior mid-stage study (FDA gave them green light to file for registration if they can do so). Soticlestat, 50-50 partnered with Takeda, has a unique mechanism of action that not only crushes seizures but also potentially heals the brain. The asset is both first-in-class and only-in-class, is targeting a large opportunity in rare epilepsies, and has shown impressive seizure reduction in prior trials (caveat for low N). ENDYMION extension data provided another element of derisking as a group of incredibly difficult to treat patients experienced increased seizure reduction with prolonged treatment. See my September article. Time Frame For Upside = 6 to 12 months as multiple data readouts come to pass (Catalyst Idea).

Soticlestat Shows Promise for Developmental Epileptic Encephalopathies

Soticlestat Shows Promise for Developmental Epileptic Encephalopathies
The director of pediatric epilepsy at Northeast Regional Epilepsy Group and co-director of epileptology at Hackensack University Medical Center spoke about soticlestat and what can be gleaned from data thus far.
By: Matt Hoffman


Published: October 17, 2019
Dr Eric SegalEric Segal, MDRecently, Ovid Therapeutics announced that its phase 2 open-label extension study of soticlestat produced initial positive results, with data suggesting that the therapy is effective over the long-term in treating patients with rare developmental epileptic encephalopathies.

Ultimately, the highly selective first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H) was associated with seizure reduction over 48 weeks in a small cohort of 7 patients. The median seizure frequency reductions were 84% after 25 to 36 weeks (n = 6) and 90% after 37 to 48 weeks (n = 4) of treatment, with 2 patients experiencing seizure-free runs of 264 and 150 consecutive days, respectively. Additionally, the safety and tolerability of soticlestat, previously known as OV935/TAK935, was consistent with the observations from the phase 1b/2a trial.

Amit Rakhit, MD, MBA, Chief Medical Officer, Head of Research & Development, Ovid, said in a statement that the clinical development program of soticlestat in developmental epileptic encephalopathies is expected to read out data from the ARCADE and ELEKTRA studies in 2020.

To learn more about soticlestat and the latest data, NeurologyLive spoke with Eric Segal, MD, director, pediatric epilepsy, Northeast Regional Epilepsy Group, co-director, epileptology, Hackensack Meridian Health, and assistant professor of pediatrics and neurology, Hackensack Meridian School of Medicine. Segal, a trial investigator for soticlestat, provided insight into the clinical takeaways and the potential of the therapy.
NeurologyLive: What does the clinician community need to know about these data and about soticlestat in general?
Eric Segal, MD: The preliminary data that we've seen thus far is very exciting for a first-in-class mechanism. We have pretty significant positive efficacy results in a small group of adult patients who typically have pretty severe epilepsies and it was well tolerated. I think all those pieces are very interesting.

Obviously, we need to see how this therapy works in larger groups of patients. That's going to be the next big thing. What I found to be the most interesting about the data was not only the significant median seizure reduction but also how seizure reduction was sustained and improved the longer the patients took on the medication. A lot of times when we look at open-label extensions, we tend to see a significant drop out in the number of patients. There's a small number of patients to start with, but the majority of those patients stayed in the study and had improvements in seizure frequency going from week 1 through week 36. That is very unique.
Are there any other specific datapoints that make this therapy stand out or make this therapy unique in this space?
There are a few things. One is that the sustained efficacy in this group of patients is significant. Especially in a group of patients with epileptic encephalopathies who tend to try or have used, and unfortunately have failed, some of our most effective medications that are available. To have such a high seizure reduction rate that is sustained in a group of people that have failed what we would think of as our strongest or most efficacious medications, I think that is very significant.
Is there a particular rare epilepsy or subgroup in which soticlestat has significant potential?
The therapy is underway in study for Lennox-Gastaut syndrome and Dravet syndrome. I would say that a lot of these rare disorders can be very difficult to treat in clinical practice. I think for most clinicians, of the potential indicated epilepsies, Lennox-Gastaut syndrome is probably going to be where you find the greatest number of patients with a great need, and it's exciting to see that this therapy is being considered for that. I'm really interested in seeing that in all the genetic epilepsies that that's being tested in. But especially in Lennox-Gastaut, given that we have such a large LGS community of patients that definitely need better therapies than are what are currently available.

Transcript edited for clarity.

https://www.neurologylive.com/clinical-focus/soticlestat-shows-promise-for-developmental-epileptic-encephalopathies

dumping shares today.......it will take a while for this unknown ticker, to absorb the 32 million offering from last week

buy /sell volume.....147k / 264k...at 3 pm.......down 11% on a decent market.......I think this has a way to go.......O S will go from 40 mill to at least 55mill

think I`ll check back in a few days......was trading $1.70`s around labor day........this will keep going down the stairs for a while.......glta

* * $OVID Video Chart 10-04-2019 * *

Link to Video - click here to watch the technical chart video

been watching this since they ran it up a few weeks ago.......didn`t buy ......could smell an OFFERING

WE GOT IT TODAY add at least another 13 million to the 40 mill O S ........nice 33% increase in share count...good job

they , like all the bio`s, have a few things in the pipe

this 27% pull back is not nearly enough, based on the new O S structure...........this belongs back at $2.....glta